KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Edwards Lifesciences (EW) Gross Profit (2016 - 2025)

Edwards Lifesciences (EW) has 17 years of Gross Profit data on record, last reported at $1.2 billion in Q4 2025.

  • For Q4 2025, Gross Profit rose 12.16% year-over-year to $1.2 billion; the TTM value through Dec 2025 reached $4.7 billion, up 9.52%, while the annual FY2025 figure was $4.7 billion, 9.52% up from the prior year.
  • Gross Profit reached $1.2 billion in Q4 2025 per EW's latest filing, up from $1.2 billion in the prior quarter.
  • Across five years, Gross Profit topped out at $1.2 billion in Q4 2025 and bottomed at $528.7 million in Q4 2022.
  • Average Gross Profit over 5 years is $1.0 billion, with a median of $1.0 billion recorded in 2022.
  • Peak YoY movement for Gross Profit: crashed 48.18% in 2022, then soared 92.06% in 2023.
  • A 5-year view of Gross Profit shows it stood at $1.0 billion in 2021, then tumbled by 48.18% to $528.7 million in 2022, then surged by 92.06% to $1.0 billion in 2023, then increased by 7.7% to $1.1 billion in 2024, then rose by 12.16% to $1.2 billion in 2025.
  • Per Business Quant database, its latest 3 readings for Gross Profit were $1.2 billion in Q4 2025, $1.2 billion in Q3 2025, and $1.2 billion in Q2 2025.